Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

the average weight loss was 22.2 kg (48.9 lb), and for Zepbound’s 15mg weekly dose average weight loss was 23.6 kg (52.0 lb) over 72 weeks. Patients who used a placebo lost 2.4 kg (5.3 lb ...

Zepbound is a GLP-1 agonist containing tirzepatide ... Doses may continue to increase to a maximum of 15 mg per week, based on individual needs. Common side effects include nausea, diarrhea ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Doses may continue to increase to a maximum of 15 mg per week, based on individual ... For a complete list of side effects, refer to the Zepbound medication guide. Adults with a BMI over 30 ...

rival drug Zepbound at its 15mg dose, the analyst tells investors in a research note. It still will take time before Novo Nordisk submits CagriSema to regulatory authorities, but the firm is ...

In the 176-week study run over three years – which underpinned tirzepatide's approval for obesity last year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg ...